Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial
Authors
Rugo, H. S.Oliveira, M.
Howell, Sacha J
Dalenc, F.
Cortes, J.
Gomez, H. L.
Hu, X. C.
Iwata, H.
Jhaveri, K. L.
Loibl, S.
Murillo, S. M.
Okera, M.
Park, Y. H.
Sohn, J.
Zhukova, L.
Logan, J.
Twomey, K.
Khatun, M.
D'Cruz, C. M.
Turner, N. C.
Affiliation
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San FranciscoIssue Date
2023
Metadata
Show full item recordCitation
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000178.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.1067Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1067Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.1067